Page 37 - Test PDF v5

« Back to Contents CERVICAL CANCER

LiFE re

Literature for ENYGO

Pathology of cervical cancer

Relevant articles retrieved Nov 2015 - Feb 2016

No Title Authors Journal Link to abstract

1 Age-specific prevalence of HPV16/18 genotypes in cervical cancer: a syste- Hammer A et al. Int J Cancer. http://www.ncbi.nlm.nih.gov/
matic review and meta-analysis. pubmed/26661889

2 Secular trends of HPV genotypes in invasive cervical cancer in Cali, Colombia Sanchez GI et al. Cancer Epidemiol. http://www.ncbi.nlm.nih.gov/
1950-1999. pubmed/26771314

3 Prevalence of human papillomavirus genotypes among women with cervical Awua AK et al. Infect Agent Cancer. http://www.ncbi.nlm.nih.gov/
cancer in Ghana. pubmed/26816527

4 Prevalence of human papilloma virus (HPV) and its genotypes in cervical Youssef MA et al. Infect Agent Cancer. http://www.ncbi.nlm.nih.gov/
specimens of Egyptian women by linear array HPV genotyping test. pubmed/26889206

5 HPV prevalence and type-distribution in cervical cancer and premalignant Anderson LA et al. J Med Virol. http://www.ncbi.nlm.nih.gov/
lesions of the cervix: A population-based study from Northern Ireland. pubmed/26680281

6 Detection and Typing of Human Papilloma Viruses by Nested Multiplex Jalal Kiani S et al. Jundishapur J Microbiol. http://www.ncbi.nlm.nih.gov/
Polymerase Chain Reaction Assay in Cervical Cancer. pubmed/26865940

7 Hypoxia inducible factor-1 mediates upregulation of urokinase-type plasmino- Nishi H et al. Oncol Rep. http://www.ncbi.nlm.nih.gov/
gen activator receptor gene transcription during hypoxia in cervical cancer pubmed/26718775
cells.
http://www.ncbi.nlm.nih.gov/
8 Stromal Fibroblasts Induce CCL20 through IL6/C/EBPβ to Support the Walch-Rückheim B et al. Cancer Res pubmed/26631268
Recruitment of Th17 Cells during Cervical Cancer Progression.
http://www.ncbi.nlm.nih.gov/
9 Roles of CDKN1A gene polymorphisms (rs1801270 and rs1059234) in the Vargas-Torres SL et al. Tumour Biol. pubmed/26846214
development of cervical neoplasia.
http://www.ncbi.nlm.nih.gov/
10 Correlation of IL-27 genetic polymorphisms with the risk and survival of Shi J, Yuan M et al. Tumour Biol. pubmed/26662568
cervical cancer in a Chinese Han population.
http://www.ncbi.nlm.nih.gov/
11 Expressions of E2 and E7-HPV16 proteins in pre-malignant and malignant Ramirez N et al. Biotech Histochem. pubmed/26052817
lesions of the uterine cervix.
http://www.ncbi.nlm.nih.gov/
12 CADM1 and MAL methylation status in cervical scrapes is representative of van Baars R et al. Int J Cancer. pubmed/26219541
the most severe underlying lesion in women with multiple cervical biopsies.
http://www.ncbi.nlm.nih.gov/
13 A study of the expression and localization of toll-like receptors 2 and 9 in Ghosh A et al. Exp Mol Pathol pubmed/26569074
different grades of cervical intraepithelial neoplasia and squamous cell
carcinoma. http://www.ncbi.nlm.nih.gov/
pubmed/26851753
14 5-Hydroxymethylcytosine expression is associated with poor survival in Zhang LY et al. Jpn J Clin Oncol.
cervical squamous cell carcinoma. http://www.ncbi.nlm.nih.gov/
pubmed/26254281
15 Prognostic significance of TRAIL signalling molecules in cervical squamous Yao Q et al. J Clin Pathol
cell carcinoma. http://www.ncbi.nlm.nih.gov/
pubmed/26799253
16 Overexpression of Eukaryotic Initiation Factor 5A2 is associated with cancer Yang S et al. Histopathology.
progression and poor prognosis in patients with early-stage cervical cancer. http://www.ncbi.nlm.nih.gov/
pubmed/26867665
17 Influence of Ku86 and XRCC4 expression in uterine cervical cancer on the Takada Y et al. Med Mol Morphol.
response to preoperative radiotherapy. http://www.ncbi.nlm.nih.gov/
pubmed/26666576
18 The significance of G-CSF expression and myeloid-derived suppressor cells in Kawano M et al. Sci Rep.
the chemoresistance of uterine cervical cancer. http://www.ncbi.nlm.nih.gov/
pubmed/26862945
19 Prostate-specific Membrane Antigen (PSMA) Expression in the Neovasculatu- Wernicke AG et al. Appl Immunohistochem Mol
re of Gynecologic Malignancies: Implications for PSMA-targeted Therapy. Morphol. http://www.ncbi.nlm.nih.gov/
pubmed/26849232
20 Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is Asano T et al. Oncotarget.
involved in cervical cancer stemness and can be a target of immunotherapy.

International Journal of Gynecological Cancer, Volume 26, Supplement #1 Page 37